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The global pandemic COVID-19 has resulted in significant global morbidity, mortality 
and increased healthcare demands. There is now emerging evidence in of patients 
experiencing urticaria. We sought to systematically review current evidence, critique 
the literature and present out findings. 
 
Methods  
Allowing PRISMA guidelines, a comprehensive literature search was carried out with 
Medline, EMBASE, Scopus, Cochrane, and Google Scholar, using key MeSH words, 
which include “COVID-19,” “Coronavirus”, “SARS-Cov-2”, “Urticaria,” “Angioedema,” 
“Skin rash” up to August, 01 2020. The key inclusion criteria were articles that 
reported on urticaria and/or angioedema due to COVID-19 infection and reported 
management and outcome. Studies were excluded if no case or cohort outcomes 
were observed.  
 
Results  
Our search returned 169 articles, 25 of which met inclusion criteria. All studies were 
case reports, reporting 26 patients with urticaria and/or angioedema and COVID-19 
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infection and their management and/or response. Majority of patients (n=16, 69%) 
were over 50 years old. However, urticaria in the younger ages was not uncommon, 
with reported case of 2 months old infant. Skin lesions resolved from less than 24 
hours to up to 2 weeks following treatment with antihistamines and/or steroids. There 
have been no cases of recurrent urticaria or cases non-responsive to steroids. 
 
Conclusions  
Management of urticarial in COVID-19 patients should involve antihistamines. Low 
dose prednisolone should be considered on an individualised basis. Further research 
is required in understanding urticarial pathogenesis in COVID-19. This will aid early 
diagnostic assessment in patients with high index of suspicion and subsequent 
management in the acute phase. 
 
 




















The global pandemic COVID-19 is caused by severe acute respiratory syndrome 
coronavirus-2 (SARS-COV2). It has resulted in global morbidity, mortality and 
significantly increased healthcare demands.1 It was originally reported that the main 
symptoms of COVID-19 to be a cough and fever. However, as the pandemic 
progressed, our understanding of COVID-19 increased, leading to anosmia and/or 
hyposmia established as a third symptom. As our understanding of this disease 
increases, it is reported that SARS-COV2 can present with clinical manifestations 
beyond the respiratory system. We are now aware that neurological manifestation can 
develop which encompasses acute skeletal muscle injury as well as an impaired 
consciousness.2  Additionally, severe infections can have an impact on renal and 
cardiac function.3  
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More recently, there has been a growing interest regarding the dermatological 
manifestations in patients with COVID-19. Skin manifestations during the course of a 
COVID-19 infection was first reported in China, however the prevalence was low at 
0.2% cases out of 1099 cases.4 There is now emerging evidence in literature making 
reference to some patients experiencing urticaria. Urticaria manifests itself as urticarial 
plaques that affect the upper dermis which can cover the skin and mucous 
membranes. It is described as erythematous and pruritic, and can sometimes present 
with angioedema, a type of swelling of the dermis subcutaneous tissue, the mucosa, 
and submucosal tissues.5  
  
The objective of this systematic review is to review the current literature on urticaria in 
COVID-19 patients. Furthermore, we aim to provide insight into urticarial pathogenesis 
and management in such patients. 
 
2. Methods  
2.1 Literature Search  
This study was done according to Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) method identifying published literature on urticaria 
and/or angioedema due to COVID-19 infection and its management and outcomes. 
The comprehensive literature search was carried out with Medline, EMBASE, 
Scopus, Cochrane database, and Google Scholar, using key MeSH words, which 
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include “COVID-19,” “Coronavirus”, “SARS-Cov-2”, “Urticaria,” “Angioedema,” “Skin 
rash”. Manual cross checking of reference lists of relevant articles was performed. All 
published articles have been reviewed, and the findings have been included in this 
study. The relevant articles have been cited and referenced within this study. The 
limits included studies in English and articles published after December 2019 until 
August 01, 2020. All the relevant articles identified were analysed by two authors, 
and the results were appropriately summarised and reported.  
2.2 Inclusion and Exclusion Criteria  
The key inclusion criteria were articles that reported on urticaria and/or angioedema 
due to COVID-19 infection and reported management and outcome, and studies 
were excluded if no case or cohort outcomes were observed. Other exclusion criteria 
were consensus documents, editorials, commentaries, and narrative reviews. 
2.3 Data Extraction  
All studies were screened by 2 authors independently (E.A. and A.D); disagreement 
was resolved by consensus or involvement of other authors (R.S. and A.H.). The 
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Following an extensive database search, 169 articles were identified.  Of these, 34 
were selected for full text review based on their title and abstract. Full text screening 
resulted in the final selection of 25 articles (Figure 1),6-25 reporting 26 patients with 
urticaria and/or angioedema and COVID-19 infection and their management plan 
and/or response to management. Table 1 includes the summarised key findings of 
the studies included in this review. All included articles were case reports. 
The majority of patients (n=16, 69%) were over 50 years old. However, urticaria in 
the younger ages was not uncommon, with reported case of 2 months old girl. Skin 
lesions were reported resolve from less than 24 hours to up to 2 weeks following 
treatment with antihistamines and/or steroids. There have been no cases of 




4.1 Demographic of COVID-19 patients with urticaria development. 
The review population revealed that the majority of patients (18 patients) affected by 
urticaria were over 50 years old. However, urticaria in the younger ages was not 
uncommon. Typically, urticaria has a peak onset of 20-40 years and affects females 
more than males, which was found to be the case in this review. Lifetime incidence 
of urticaria is reported to be 15%.31 It has been reported that urticaria may be a rare 
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manifestation of COVID-19, which has been observed in just under 4% of COVID-19 
patients.32 
Of note, most case reports have found skin manifestations to not be associated with 
disease severity32,28 Conversely, a prospective Spanish cohort study reported that the 
presentation of urticaria and maculopapular skin lesions were associated with higher 
morbidity (severe COVID-19 illness) and higher mortality rate (2%).33 Further 
observational studies will aid further understanding of the association of COVID-19 
disease progression and dermatological manifestations. 
 
4.2 Pathophysiology of urticaria in COVID-19  
The pathophysiology was previously hypothesised to be attributed to drug-induced 
urticaria. Urticaria is a well-known cutaneous manifestation of a drug eruption [34], 
however urticaria has been debated in COVID-19 patients as to whether the virus 
directly results in urticaria, or if urticaria is caused by a drug eruption. There have been 
reports of COVID-19 positive cases with urticaria, where there had been no changes 
in their medication regime.25, 32 This may suggest that urticaria could be directly related 
to the pathogenesis of the SARS-CoV2. However, individual case reports have 
reported urticaria manifestation prior to commencement of therapy for COVID-19 as 
well as reports of remission from urticaria despite continuation of drug therapy.28 This 
suggests that urticaria in COVID-19 is likely multifactorial and drug-associated skin 
manifestations to not account for all cases.  
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SARS-CoV-2 entry into a cell is mediated through binding to angiotensin-converting 
enzyme-2 (ACE2) protein and subsequent endocytosis in epithelial targets in the 
lung.35 Of note, systemic response may be owed to the presentation of ACE2 on other 
tissues, including kidney, brain and importantly, the vasculature. Angiotensin (Ang) I 
and Ang II are deactivated by ACE2 Ang I and Ang II are associated with inflammation, 
oxidative stress and fibrotic scarring.36 In the instance of coronavirus infection, the 
binding of SARS-CoV-2 with ACE2 disrupts normal ACE2 activity. This may result in 
increased activity of Ang II, leading to formation of reactive oxygen species, disrupt 
antioxidant and vasodilatory molecules and result in complement activation.37 Such 
disrupted physiological processes were observed in a rat model with aberrant 
expression of Ang II.38  
COVID-19 associated skin manifestations may be mediated by the systemic 
inflammatory response that follows the human body’s response to an acute infection.39 
This includes activation of the complement system and adjustment of the cytokine-
chemokine milieu.9 Consequently, this progresses to aberrant activation and 
sequential degranulation of mast cells. It is hypothesised that mast cell degranulation 
is the principal pathophysiology associated with subsequent systemic organ damage 
in COVID-19.40 Of note, most patients with COVID-19 were reported to have elevated 
levels of circulating interleukin-6 (IL-6).41 Furthermore, colocalization of SARS-CoV-2 
glycoproteins and respective complement mediators have been reported in peripheral 
cutaneous blood vessels.42 Therefore, it is possible that these mediators may be 
attributed to urticarial pathogenesis.  
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Urticaria has sometimes been associated with eosinophilia (>500 eosinophils/mm3), 
which has been observed in a number of COVID-19 cases [43]. Moreover, eosinophilia 
seems to have a protective mechanism and has been associated with a better 
prognosis.44 There have also been some cases where patients initially presented with 
urticaria only before experiencing the typical COVID-19 symptoms and testing 
positive. What was evident in these cases was that they had been taking some form 
of prescribed medication prior to testing positive to COVID-19.45, 46 Despite some 
patients having no medication changes, they still were taking medication at the time 
of onset of urticaria, suggesting that COVID-19 may cause eosinophilia, resulting in 
drug hypersensitivity and thus urticaria. However, more research is needed to formally 
establish this relation.  
 
4.3 Diagnosis assessment 
It is important to ensure that urticaria is correctly diagnosed so that appropriate 
treatment can be administered. A diagnostic characteristic of urticaria is that the 
cutaneous lesions must be evanescent. Multiple case reports have not detailed this 
characteristic in their studies, so it is important this is taken into consideration. 
Furthermore, some case reports have mentioned how a skin biopsy for 
histopathological studies may aid in a diagnosis of urticaria.47 One case report has 
discussed that a skin biopsy of a COVID-19 patient with urticaria revealed perivascular 
infiltrate of lymphocytes, some eosinophils and upper dermal oedema.48 A skin biopsy 
and awareness of evanescent lesions may allow for the differentiation to be made 
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between urticaria and other cutaneous manifestations, limiting the chance of a 
misdiagnosis.  
 
On clinical assessment clinicians should consider the possibility of glucose-6-pyruvate 
dehydrogenase (G6PD) deficiency in COVID-19 patients as this group of patients may 
have a dominance of high-producing IL-6 allele. In one study group, this correlation 
has been reported in 71% of patients49. 
 
4.4 Patient management 
Classically, the recommended algorithm for treating urticaria includes the use of 
second-generation antihistamines, and if inadequate control within 2-4 weeks, the 
dose can be increased up to four times the original dose. If this is still inadequate 
control after a further 2-4 weeks, specialist referral should be considered, where 
specialists can consider prescribing omalizumab and ciclosporin to help alleviate 
symptoms.50 However, in most patients, second generation oral antihistamines 
provide adequate control of urticaria.51 The pathophysiology of COVID-19 related 
urticaria demonstrates that antihistamines alone will not stop mast cell histamine 
degranulation but will only act to reduce the severity of urticaria.  
 
Low systemic steroids, on the other hand, targets the COVID-19 inflammatory storm, 
which prevents mast cell activation, and thus histamine release. Therefore, low dose 
systemic steroids may be able to effectively manage urticaria in COVID-19 through 
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their proposed mechanism of action. Combining this with antihistamines can improve 
patients’ clinical response to urticaria9. A further benefit of low dose steroids, shown 
through a randomised control trial, has demonstrated an increase in survival rate in 
COVID-19 patients (Randomised Evaluation of COVID-19 Therapy (RECOVERY), 
ClinicalTrials.gov Identifier: NCT04381936). Although corticosteroids are promising, it 
may increase the risk of prolonged viral replication, so it may be best to use them for 
the shortest duration possible until symptoms are controlled. After this, consideration 
should be made to promptly switch to omalizumab. Ciclosporin is currently not 
recommended in COVID-19 patients.51 
 
4.5 Limitations 
All included articles were case. Only three case reports detailed pathological study 
results.8,12,27 A diagnostic characteristic of urticaria is that the cutaneous lesions 
must be evanescent (no one lesion should last more than 24 hours), however this 




Urticaria is a significant manifestation of COVID-19, notably affecting patient morbidity. 
As such the clinical presentation of urticaria can aid diagnostic assessment, whist 
considering risk factors, such as G6PD deficiency and aberrant IL-6 expression. 
Management of COVID-19 patients should involve antihistamines. Low dose 
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prednisolone should be considered on an individualised basis. further research is 
required in understanding urticarial pathogenesis in COVID-19. This will aid early 
diagnostic assessment in patients with high index of suspicion and subsequent 
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last 
immunotherapy 
dose - ipilimumab 
(1 mg/kg every 6 
Serial ferritin, D-Dimer 
(DD), and IL6 in 
addition to ANAS and 


































nuclear debris.   
weeks) plus 
nivolumab (3 




were evaluated.  
 
Elevation of ferritin (940 
ng/mL) and DD (2.600 




(400 mg BID on day 
1200 mg BID for 14 
days)  
 
Azithromycin (500 mg 



















IL6 levels by 
ELISA only 
had a slightly 
elevated value 

















lady with a 5-









on the trunk 
and 
extremities 












within 5 days 
 
5 days 
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chronic 
urticaria  
 and sparing 
of the face, 
palm, and 
sole 








with history of 
hayfever and 







itchy rash with 
angioedema of 























two to four times per 
day. 
Rash worsened 




Advised to continue 
taking fexofenadine 
hydrochloride 180 mg 
four times per day and 
she was commenced 
on prednisolone 40mg 
once daily for 3 days.  
 
Prednisolone helped lip 
and hand swelling, but 
rash remained itchy. 
 
Chlorphenamine 
maleate 4mg four 
times/day was 







over next few 
days. The 

















At same time 
as COVID-19 
symptoms 
Not reported Not reported Initial biochemical tests 
showed low numbers of 
white blood cells (WBC) 
Not reported Not 
reported 
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of face and 
nceck   
(WBC = 2.75 × 103). 
Lymphopenia was 
detected 
(lymphocytes = 852). 
 
RT‐PCR for COVID‐19 
was not performed. 
 
CT chest was carried 
out, which showed 
pneumonia with 
bilateral and subpleural 
areas of ground‐glass 
opacification, 
consolidation affecting 
the lower lobes and 
confirming the 


























> 5 days after 
first reporting 
covid-19 























for 5 days 
 
A sudden worsening of 
respiratory condition led 
to the patient’s death, 
and therefore, no 




























14 days after 
first reporting 
covid-19 



















Not reported Therapy with 
hydroxychloroquine and 
azithromycin was 





administered for his 
skin condition. 













woman with a 
3‐day history 
































 The patient had 
not taken any 
medication before 
the onset of the 
symptoms.  
 





Blood test showed 
lymphopenia 
and elevated C‐reactive 
protein (5.4 mg/l) and 







of pruritus and 
resolution of 
skin lesions 
within 2 days. 
 


























loratadine 10 mg every 
12 hours  
 
 



















































urticaria – possible 
reaction to 
medication?) 












Generalised 1 day after 
admission  
 




Not reported Not 
reported 















as unspecific viral rash 
due to COVID‐19 and 
included as differential 
diagnosis a drug 












Generalised During course 
of COVID-19 




e treatment for 




















oseltamivir in intensive 
care unit for 7 days. 
 
As etiology of her 
diffuse urticaria, viral 
infection itself, drugs 
she received, and 
psychological stress of 
the clinical condition 
were considered 
 















Generalised 3 days before 
admission and 




































The patient did 
not report neither 
similar episodes in 
the past, nor 
allergies to drugs 
or foods.  
 
 
scan of the chest 




Blood test revealed 







reactive protein (CRP, 
12.1 mg/dL), and liver 
enzymes (GOT, GPT, 
LDH, GGT fourfold 
levels). 
 
A systemic treatment 
with intravenous daily 
administration of 
betamethasone sodium 
phosphate 4 mg and 
chlorphenamine 
maleate 10 mg, in 



















Generalised Skin rash was 
already 
present at the 
time of 




e from 1 week, 
Blood test revealed 




















and no new drug 
introduction had 
been made in the 
last 3 weeks 




No history of 
allergy to drugs or 
foods, nor recent 
intake of new 
drugs 
 
8.600/mm3), and mild 
lymphopenia 
(lymphocites 700/mm3), 
moderate increase of 
pro‐calcitonin serum 
levels (0.87 ng/mL), 
marked increase of 
CRP (10.2 mg/dL), and 
liver enzymes (GOT, 
GPT, LDH, GGT 






















































1st episode: 5 
days after 
contact with. 
covid-19  ICU 
patient  
 






same time as 
Not reported Not reported 1st episode: 
betamethasone cream 
0.1% once a day 
 
2nd episode:  
Bilastine 20 mg one 
tablet a day for 
15 days. 
betamethasone 
ointment 0.1% cream 
once a day for 2 days 
Confirmation of COVID-






2nd episode:  
Within 48 h, 







































Patient 1 was 
a 50‐year‐old 
woman, and 






























Not reported Neither patient 
had any history of 
similar lesions, 
and no trigger 
factors other than 




























Not reported No previous 
history of atopic 
conditions 




Treatment was started 
with diagnosis of 
COVID‐19  
On the fourth 






the fifth day of 
his admission 
4 days 

























triggers other than 
viral infection 
were found, as 
there was no 
history of food 
allergy, drug 
allergy, chronic 
urticaria, nor other 
allergies. There 
was no history of 
consuming new 
medicine in 
15 days prior 
besides COVID‐













loratadine was added to 
his treatment with 
improvement of 
symptom on the next 
day. The suspicion of 
urticaria caused by the 
medicines given in 
hospital could be 
eliminated by the fact 
his urticaria improved 
even the medicines 
continued to be given. 
 
improvement 
of symptom on 




























Not reported No relevant past 
medical history 
except for pine 
seeds allergy, 
following a strict 




(ebastine 10 mg ter in 
die) 
 
24 hours after 






started to fade 
24 
hours 







region and mild 





cords, or the 
airway.  
 




Not on any 
medication.  
 








15 days.  
 
She had not 
exercised, had not 
drunk alcohol, nor 
was on menstrual 
period. 






























Not reported Acetaminophen  No signs of dyspnea, 
and the vital signs 
(including saturation) 




treatment with only 
acetaminophen was 
prescribed 7th 
postpartum day prior 
development of rash.  






of the general 
symptoms and 
absence of 
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did not show 
any symptom 
of the disease 







































No treatment  Fever and 
rash resolved 






























Not reported Not reported No drug during 





the next week. 
Cutaneous 
rash resolved 
in 7 days.  
 















rash, large,  
Trunk, head, 
upper  
and lower  
extremities  
 





Not reported Estradiol, for 
many months and 
allergy to propofol.  
 
No recent 






















lesions did not 










2- month old 
girl 
 







spread in a 








4 days after 
low fever, at  









24 h, and the 
cutaneous 
manifestations 
resolved in 5 














































medical history  
 
Taken no 
medications in the 
days and weeks 




sulfate 200 mg three 
times per day for 






































Generalised At same time 
as COVID-19 
symptoms 
Not reported No change in her 




























Not reported No triggers except 


































He had no 
other sites of 
swelling and 
had no rash.  
 








protein and D-dimer. 
Functional C1 inhibitor 
levels (59.7 mg/dL), C3 
levels (206 mg/dL), and 
C4 levels (46 mg/dL) 
were all elevated. 
By hospital 





































Figure 1. Article selection flowchart (PRISMA) 
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